Mesenchymal stem/stromal cells protect the ocular surface by suppressing inflammation in an experimental dry eye

Molecular Therapy

Volumn 23, Issue 1, 2015, Pages 139-146

  Lee, Min Joung ^a   Ko, Ah Young ^b   Ko, Jung Hwa ^b   Lee, Hyun Ju ^b   Kim, Mee Kum ^b   Wee, Won Ryang ^b   Khwarg, Sang In ^b   Oh, Joo Youn ^b  

^a Hallym University   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CONCANAVALIN A; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CORNEA EPITHELIUM; CYTOKINE RELEASE; DRY EYE; EYE INFLAMMATION; EYE PROTECTION; FEMALE; GOBLET CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LACRIMATION; LYMPHOCYTIC INFILTRATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; THERAPY EFFECT; ANIMAL; BAGG ALBINO MOUSE; CELL MOTION; CHEMICALLY INDUCED; CONJUNCTIVA; CORNEA; CYTOLOGY; DRY EYE SYNDROMES; IMMUNOLOGY; INFLAMMATION; INTRAOCULAR DRUG ADMINISTRATION; MESENCHYMAL STROMA CELL; PATHOLOGY;

MURINAE;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CONCANAVALIN A; CONJUNCTIVA; CORNEA; DRY EYE SYNDROMES; FEMALE; GOBLET CELLS; INFLAMMATION; INJECTIONS, INTRAOCULAR; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED BALB C;

EID: 84920649987     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.159     Document Type: Article

References (32)

1. Gayton, JL (2009). Etiology, prevalence, and treatment of dry eye disease. Clin Ophthalmol 3: 405-412.
2. Lin, PY, Tsai, SY, Cheng, CY, Liu, JH, Chou, P and Hsu, WM (2003). Prevalence of dry eye among an elderly Chinese population in Taiwan: the Shihpai Eye Study. Ophthalmology 110: 1096-1101.
3. McCarty, CA, Bansal, AK, Livingston, PM, Stanislavsky, YL and Taylor, HR (1998). The epidemiology of dry eye in Melbourne, Australia. Ophthalmology 105: 1114-1119.
4. Moss, SE, Klein, R and Klein, BE (2004). Incidence of dry eye in an older population. Arch Ophthalmol 122: 369-373.
5. Schaumberg, DA, Sullivan, DA, Buring, JE and Dana, MR (2003). Prevalence of dry eye syndrome among US women. Am J Ophthalmol 136: 318-326.
6. Shimmura, S, Shimazaki, J and Tsubota, K (1999). Results of a population-based questionnaire on the symptoms and lifestyles associated with dry eye. Cornea 18: 408-411.
7. Uchino, M, Schaumberg, DA, Dogru, M, Uchino, Y, Fukagawa, K, Shimmura, S et al. (2008). Prevalence of dry eye disease among Japanese visual display terminal users. Ophthalmology 115: 1982-1988.
8. Schaumberg, DA, Dana, R, Buring, JE and Sullivan, DA (2009). Prevalence of dry eye disease among US men: estimates from the Physicians' Health Studies. Arch Ophthalmol 127: 763-768.
9. Moss, SE, Klein, R and Klein, BE (2008). Long-term incidence of dry eye in an older population. Optom Vis Sci 85: 668-674.
10. Pfugfelder, SC (2008). Prevalence, burden, and pharmacoeconomics of dry eye disease. Am J Manag Care 14(3 Suppl): S102-S106.
11. Schiffman, RM, Walt, JG, Jacobsen, G, Doyle, JJ, Lebovics, G and Sumner, W (2003). Utility assessment among patients with dry eye disease. Ophthalmology 110: 1412-1419.
12. Mertzanis, P, Abetz, L, Rajagopalan, K, Espindle, D, Chalmers, R, Snyder, C et al. (2005). The relative burden of dry eye in patients' lives: comparisons to a U.S. normative sample. Invest Ophthalmol Vis Sci 46: 46-50.
13. Miljanovic, B, Dana, R, Sullivan, DA and Schaumberg, DA (2007). Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol 143: 409-415.
14. Barabino, S, Chen, Y, Chauhan, S and Dana, R (2012). Ocular surface immunity: homeostatic mechanisms and their disruption in dry eye disease. Prog Retin Eye Res 31: 271-285.
15. Stern, ME, Schaumburg, CS and Pfugfelder, SC (2013). Dry eye as a mucosal autoimmune disease. Int Rev Immunol 32: 19-41.
16. Prockop, DJ, Kota, DJ, Bazhanov, N and Reger, RL (2010). Evolving paradigms for repair of tissues by adult stem/progenitor cells (MSCs). J Cell Mol Med 14: 2190-2199.
17. Uccelli, A, Moretta, L and Pistoia, V (2006). Immunoregulatory function of mesenchymal stem cells. Eur J Immunol 36: 2566-2573.
18. Prockop, DJ and Oh, JY (2012). Mesenchymal stem/stromal cells (MSCs): role as guardians of infammation. Mol Ther 20: 14-20.
19. Bemer, V and Truffa-Bachi, P (1996). T cell activation by concanavalin A in the presence of cyclosporin A: immunosuppressor withdrawal induces NFATp translocation and interleukin-2 gene transcription. Eur J Immunol 26: 1481-1488.
20. Pfugfelder, SC, Corrales, RM and de Paiva, CS (2013). T helper cytokines in dry eye disease. Exp Eye Res 117: 118-125.
21. Meisel, R, Zibert, A, Laryea, M, Göbel, U, Däubener, W and Dilloo, D (2004). Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2, 3-dioxygenase-mediated tryptophan degradation. Blood 103: 4619-4621.
22. Popp, FC, Eggenhofer, E, Renner, P, Slowik, P, Lang, SA, Kaspar, H et al. (2008). Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate. Transpl Immunol 20: 55-60.
23. Ge, W, Jiang, J, Arp, J, Liu, W, Garcia, B and Wang, H (2010). Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2, 3-dioxygenase expression. Transplantation 90: 1312-1320.
24. Schrader, S, Mircheff, AK and Geerling, G (2008). Animal models of dry eye. Dev Ophthalmol 41: 298-312.
25. Prevosto, C, Zancolli, M, Canevali, P, Zocchi, MR and Poggi, A (2007). Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica 92: 881-888.
26. English, K, Ryan, JM, Tobin, L, Murphy, MJ, Barry, FP and Mahon, BP (2009). Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol 156: 149-160.
27. Maccario, R, Podestà, M, Moretta, A, Cometa, A, Comoli, P, Montagna, D et al. (2005). Interaction of human mesenchymal stem cells with cells involved in alloantigen-specifc immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 90: 516-525.
28. Di Ianni, M, Del Papa, B, De Ioanni, M, Moretti, L, Bonifacio, E, Cecchini, D et al. (2008). Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol 36: 309-318.
29. Németh, K, Leelahavanichkul, A, Yuen, PS, Mayer, B, Parmelee, A, Doi, K et al. (2009). Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 15: 42-49.
30. Ren, G, Su, J, Zhang, L, Zhao, X, Ling, W, L'huillie, A et al. (2009). Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 27: 1954-1962.
31. Peister, A, Mellad, JA, Larson, BL, Hall, BM, Gibson, LF and Prockop, DJ (2004). Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. Blood 103: 1662-1668.
32. Lee, RH, Pulin, AA, Seo, MJ, Kota, DJ, Ylostalo, J, Larson, BL et al. (2009). Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-infammatory protein TSG-6. Cell Stem Cell 5: 54-63.